Opthea Appoints John Han as VP Medical Affairs

Ticker: OPTEY · Form: 6-K · Filed: Apr 9, 2024 · CIK: 1815620

Sentiment: neutral

Topics: personnel, appointment, biotech

TL;DR

Opthea beefs up medical affairs with new VP John Han.

AI Summary

Opthea Limited announced on April 9, 2024, the appointment of John Han, PharmD, as its new Vice President of Medical Affairs. Dr. Han brings extensive experience in the biopharmaceutical industry, particularly in the development and commercialization of therapies for retinal diseases.

Why It Matters

The appointment of a seasoned executive like John Han to lead Medical Affairs suggests Opthea is strengthening its team for potential future product launches and market engagement.

Risk Assessment

Risk Level: low — This filing is an administrative update regarding a personnel appointment and does not contain significant financial or operational news.

Key Players & Entities

FAQ

What is the primary role of John Han, PharmD, at Opthea Limited?

John Han, PharmD, has been appointed as the Vice President of Medical Affairs at Opthea Limited.

When was this appointment announced?

The appointment was announced in a press release filed on April 9, 2024.

What is Opthea Limited's primary business sector?

Opthea Limited is in the Biological Products (no diagnostic substances) sector, SIC code 2836.

Where is Opthea Limited's principal executive office located?

Opthea Limited's principal executive office is located at Level 4, 650 Chapel Street, South Yarra, Victoria, 3141, Australia.

Does Opthea Limited file annual reports under Form 20-F or 40-F?

Opthea Limited files annual reports under Form 20-F.

Filing Stats: 151 words · 1 min read · ~1 pages · Grade level 13.1 · Accepted 2024-04-08 18:28:38

Filing Documents

SIGNATURES

SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereto duly authorized. OPTHEA LIMITED (Registrant) By: /s/ Frederic Guerard Name: Frederic Guerard Title: Chief Executive Officer Date: 04/09/2024

View Full Filing

View this 6-K filing on SEC EDGAR

View on Read The Filing